Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Open
-
A Phase 1 Multiple Dose Study To Evaluate The Safety And Tolerability Of XmAb819 In Subjects With Relapsed Or Refractory Clear Cell Renal Cell Carcinoma
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
-
Obesity And Inflammation Impact Immunotherapy Outcomes In Renal Cancer
Scottsdale/Phoenix, AZ
The purpose of this study is to determine the extent to which immunotherapy failure in kidney cancer patients with obesity is associated with prolonged, body-wide inflammation. Hypothesis: In patients with obesity, high sustained inflammation will be associated with poor immunotherapy outcomes, high inflammation that resolves during therapy will be associated with better outcomes, and sustained low inflammation will be associated with the best therapy outcomes. These general trends will also hold true for non-obese RCC patients, although the magnitude of the response rates may be shifted.
Closed for Enrollment
-
A Phase 1 Study Of JNJ-69086420, An Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (HK2) For Advanced Prostate Cancer
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D\[s\]) of JNJ-69086420 in Part 1 (Dose Escalation) and to determine safety and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose Expansion).
-
A Phase 1/2, Open-Label Study To Investigate The Safety, Tolerability, Pharmacokinetics, Biological And Clinical Activity Of DF9001 As A Monotherapy And In Combination With Nivolumab In Patients With Advanced Solid Tumors, And Expansion In Selected Indications
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to determine if a new molecule that targets natural killer (NK) cells and T-cell activation signals to specific receptors on cancer cells. The study will occur in two phases. The first phase will be a dose escalation phase, enrolling patients with various types of solid tumors that express epidermal growth factor receptor (EGFR). A combination therapy cohort will be opened for enrollment, DF9001 + nivolumab. The second phase will include a dose expansion using the best dose selected from the first phase of the study. Multiple cohorts will be opened with eligible patients having selected solid tumors.
-
An Open-label, Multicenter Phase 1/2 Study To Evaluate The Safety And Efficacy Of AB-2100 In Patients With Recurrent Advanced Or Metastatic Clear-cell Renal Cell Carcinoma (CcRCC)
Scottsdale/Phoenix, AZ
This is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.
-
Molecular Characterization Of Renal Cell Carcinomas And Melanomas
Scottsdale/Phoenix, AZ
Rochester, MN
The purpose of this study is to collect blood samples from Mayo Clinic patients with a diagnosis of Renal Cell Carcinoma (RCC) or Melanoma. The blood samples will be used to study immune cells which are the cells in our blood involved in protecting the body from disease and foreign invaders. The blood samples may also be used for future research of Renal Cell Carcinoma (RCC) or Melanoma at Mayo Clinic and future research at Mayo Clinic to learn about, prevent, or treat other health problems.
.